

WEST Search History

DATE: Monday, December 12, 2005

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L22	L21 and l18	64
<input type="checkbox"/>	L21	l17.ti,ab,clm.	589
<input type="checkbox"/>	L20	l17 with l1 not l15	197
<input type="checkbox"/>	L18	L17 same l1 not l15	636
<input type="checkbox"/>	L17	botulin\$ or tetan\$	6214
<input type="checkbox"/>	L16	L15 not l8	134
<input type="checkbox"/>	L15	l1 with L14	137
<input type="checkbox"/>	L14	clostrid\$ or neurotoxin	7673
<input type="checkbox"/>	L13	L12 same l11 same l7 not l8	5
<input type="checkbox"/>	L12	l4 same (l5 or l6)	18189
<input type="checkbox"/>	L11	l1 same L10	5684
<input type="checkbox"/>	L10	"single chain"	12781
<input type="checkbox"/>	L9	l3 and l8	35
<input type="checkbox"/>	L8	l4 same l5 same l6 same l7	45
<input type="checkbox"/>	L7	cleav\$ or protease or proteinase	109621
<input type="checkbox"/>	L6	endocyt\$6	4460
<input type="checkbox"/>	L5	transport\$	465490
<input type="checkbox"/>	L4	bind\$4	369800
<input type="checkbox"/>	L3	l1 with L2	32386
<input type="checkbox"/>	L2	gene or plasmid or protein	193210
<input type="checkbox"/>	L1	fus\$4 or chimer\$3	264391

END OF SEARCH HISTORY

***** Welcome to STN International *****
• *****STN Columbus *****
• FILE REGISTRY ENTERED AT 08:46:02 ON 12 DEC 2005
L1 2805 S DDDDL/QSQP
L2 3633 S DDDDK/QSQP
L3 75 S LVL/FQGP/QSQP
L4 709 S E.(2)YQS/QSQP
L5 4317 S E.(2)Y.(1)QG/QSQP
FILE 'REGISTRY' ENTERED AT 08:56:15 ON 12 DEC 2005
L6 3633 S L2
L7 75 S L3
FILE 'CA' ENTERED AT 08:58:41 ON 12 DEC 2005
L8 2132 S L2

L14 ANSWER 2 OF 3 CA COPYRIGHT 2005 ACS on STN
AN 139:207733 CA
TI Construction of recombinant single-chain toxins for use in vaccines and toxin assays
IN Shore, Clifford Charles; Quinn, Conrad Padraig; Foster, Keith Alan; Chaddock, John; Marks, Philip; Sutton, J. Mark; Stancombe, Patrick; Wayne, Jonathan
SA Microbiological Research Authority, UK; Speywood Laboratory Limited
SO U.S. Pat. Appl., 37 pp., Cont.-in-part of U.S. Ser. No. 255,829. CODEN: USXXCO
DT Patent
LA English
FAN,CNT 3 PATENT NO. KIND DATE APPLICATION NO. DATE
I US 2003166238 A1 20030904 US 2002-241596 20020912 WO 9807864 A1 19980226 WO 1997-GB2273 19970822
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG ZA
9707541 A 19980416 ZA 1997-7541 19970822 US 2002044950 A1 20020418 US 1999-255829
19990223 US 6461617 B2 20021008 CA 2498502 AA 20040325 CA 2003-2498502 20030912 WO 2004024909 A2 20040325 WO 2003-GB3824 20030912 WO 2004024909 A3 20040708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, T.J, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1537207 A2 20050608 EP 2003-748251 20030912 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK US 2005244435 A1 20051103 US 2005-77550 20050311

L17 ANSWER 1 OF 6 CA COPYRIGHT 2005 ACS on STN
TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002
L17 ANSWER 2 OF 6 CA COPYRIGHT 2005 ACS on STN
TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002
L17 ANSWER 3 OF 6 CA COPYRIGHT 2005 ACS on STN
TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002
L17 ANSWER 4 OF 6 CA COPYRIGHT 2005 ACS on STN
TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002
L17 ANSWER 5 OF 6 CA COPYRIGHT 2005 ACS on STN

L9 55 S L3
L10 268 S L4
L11 1602 S L5
L12 24744 S CLOSTRID?
L13 19 S L12 AND L8
L14 3 S L12 AND L9
L15 6 S L12 AND L10
L16 26 S L12 AND L11
L17 6 S L15 NOT L14
L18 19 S L16 NOT (L14 OR L15)
L19 10 S L13 NOT (L16 OR L14 OR L15)

L14 ANSWER 1 OF 3 CA COPYRIGHT 2005 ACS on STN

L14 ANSWER 2 OF 3 CA COPYRIGHT 2005 ACS on STN
AN 134:203683 CA
TI Recombinant construction and expression of single-chain activatable neurotoxins
IN Dolly, J. Oliver; Li, Yan; Chan, Kuo Chion
PA Allergan Sales, Inc., USA
SO PCT Int. Appl., 90 pp. CODEN: PIXXD2
DT Patent
LA English
FAN,CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2001014570 A1 20010301 WO 2000-US23427 20000825 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG CA 2380457 AA 20010301 CA 2000-2380457 20000825 BR 2000012759 A 20020402 BR 2000-12759 20000825 EP 1206554 A1 20020522 EP 2000-964920 20000825 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003507073 T2 20030225 JP 2001-518882 20000825 AU 777556 B2 20041021 AU 2000-75731 20000825
PRAI US 1999-150710P P 19990825 WO 2000-US23427 W 20000825
RE,CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 19 CA COPYRIGHT 2005 ACS on STN
TI Methods for identifying the target of a compound which inhibits cellular proliferation PY 2002 2002 2003 2004
L18 ANSWER 5 OF 19 CA COPYRIGHT 2005 ACS on STN
TI Methods for identifying the target of a compound which inhibits cellular proliferation PY 2002 2003 2002 2002 2003 2004
L18 ANSWER 6 OF 19 CA COPYRIGHT 2005 ACS on STN
TI Substituted benzimidazole compounds as transcription factor-modulating compounds useful as anti-infectives PY 2004 2004 2004 2005
L18 ANSWER 7 OF 19 CA COPYRIGHT 2005 ACS on STN
TI The genome sequence of ***Obstidium*** tetani, the causative agent of tetanus disease PY 2003
L18 ANSWER 8 OF 19 CA COPYRIGHT 2005 ACS on STN

L18 ANSWER 1 OF 19 CA COPYRIGHT 2005 ACS on STN
TI Molecular cloning and transcriptional and expression analysis of engO, encoding a new noncellulosomal family 9 enzyme, from ***Obstidium*** cellulovorans PY 2005
L18 ANSWER 2 OF 19 CA COPYRIGHT 2005 ACS on STN
TI Substituted benzimidazole compounds as transcription factor-modulating compounds useful as anti-infectives PY 2005 2002 2005 2005 2003 2004
L18 ANSWER 3 OF 19 CA COPYRIGHT 2005 ACS on STN
TI Prediction of operons in Staphylococcus aureus and other microbial genomes with use of antisense nucleic acids for identification of proliferation-required operons PY 2005

T1 Methods and compounds for the treatment of mucus hypersecretion by inhibiting mucus secretion using compounds having targeting and translocating modified light chain of ***cbsdtrial*** neurotoxin PY 2004 2000 2000 2003
L14 ANSWER 2 OF 3 CA COPYRIGHT 2005 ACS on STN
TI Construction of recombinant single-chain toxins for use in vaccines and toxin assays PY 2003 1998 1998 2002 2002 2004 2004 2005 2005
L14 ANSWER 3 OF 3 CA COPYRIGHT 2005 ACS on STN
TI Recombinant construction and expression of single-chain activatable neurotoxins PY 2001 2001 2002 2002 2003 2004
PRAI GB 1996-17671 A 19960823 GB 1996-25996 A 19961213 US 1996-782893 B2 19961227
WO 1997-GB2273 W 19970822 US 1996-242689 B1 19990223 US 1999-255829 A2 19990223 US 2002-241596 A 20020912 WO 2003-GB3824 W 20030912

TI Identification of a novel locus that regulates expression of toxin genes in perfringens PY 2002	***Clostridium***	TY 2002	L18 ANSWER 16 OF 19 CA COPYRIGHT 2005 ACS on STN TI Genes identified as required for proliferation of Escherichia coli and their use in antimicrobial drug discovery PY 2001 2002 2001 2002 2002 2003	L19 ANSWER 4 OF 10 CA COPYRIGHT 2005 ACS on STN TI Metal ion-affinity peptides and method for purification of recombinant proteins PY 2004
L18 ANSWER 9 OF 19 CA COPYRIGHT 2005 ACS on STN TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002			L18 ANSWER 17 OF 19 CA COPYRIGHT 2005 ACS on STN TI Development of novel antimicrobial agents based on bacteriophage genomics PY 2000 2001 2004 2000 2001 2002 2004	L19 ANSWER 5 OF 10 CA COPYRIGHT 2005 ACS on STN TI Targeted delivery of therapeutic agents for nerve regeneration using heavy chain (Hc) from botulinum C1 toxin as a neuron-binding domain PY 2004 2004 2004 2005 2005
L18 ANSWER 10 OF 19 CA COPYRIGHT 2005 ACS on STN TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002			L18 ANSWER 18 OF 19 CA COPYRIGHT 2005 ACS on STN TI Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof PY 1999 2002 1999 1999 2000	L19 ANSWER 6 OF 10 CA COPYRIGHT 2005 ACS on STN TI The Wisa and Sost genes involved in the regulation of bone development in the vertebrate embryo and their use in modulating patterning in development PY 2003 2005 2004
L18 ANSWER 11 OF 19 CA COPYRIGHT 2005 ACS on STN TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002			L18 ANSWER 19 OF 19 CA COPYRIGHT 2005 ACS on STN TI Cloning, DNA sequencing, and expression of the gene encoding ***Clostridium*** thermocoelum cellulase CelL, the largest catalytic component of the cellulosome PY 1996	L19 ANSWER 7 OF 10 CA COPYRIGHT 2005 ACS on STN TI Superantigen conjugates and receptors specific for lipid-based tumor-associated antigens for treatment of neoplastic disease PY 2003
L18 ANSWER 12 OF 19 CA COPYRIGHT 2005 ACS on STN TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002			L19 ANSWER 1 OF 10 CA COPYRIGHT 2005 ACS on STN TI GFP-SNAP25 fluorescence release assay for detecting botulinum neurotoxin protease activity PY 2005 2003	L19 ANSWER 8 OF 10 CA COPYRIGHT 2005 ACS on STN TI Method for structural modifying ***Clostridium*** neurotoxins for altering biological activity or persistence by leucine-based motifs PY 2002 2003 2005 2002 2003 2003 2005 2005
L18 ANSWER 13 OF 19 CA COPYRIGHT 2005 ACS on STN TI Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening PY 2002 2002 2002			L19 ANSWER 2 OF 10 CA COPYRIGHT 2005 ACS on STN TI Modifying source organisms to improve the efficiency of cell-free protein biosynthesis using cell lysates PY 2005 2005	L19 ANSWER 9 OF 10 CA COPYRIGHT 2005 ACS on STN TI Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin PY 2000
L18 ANSWER 14 OF 19 CA COPYRIGHT 2005 ACS on STN TI Genome sequence and analysis of the oral bacterium Fusobacterium nucleatum strain ATCC 25586 PY 2002			L19 ANSWER 3 OF 10 CA COPYRIGHT 2005 ACS on STN TI Optical biosensors and methods of use thereof PY 2004 2004	L19 ANSWER 10 OF 10 CA COPYRIGHT 2005 ACS on STN TI Methods for concentrating and detecting ligands using magnetic particles PY 1998 1998 2000 2002
L18 ANSWER 15 OF 19 CA COPYRIGHT 2005 ACS on STN TI Complete genome sequence of ***Clostridium*** perfringens, an anaerobic flesh-eater				
L19 ANSWER 8 OF 10 CA COPYRIGHT 2005 ACS on STN AN 136:156405 CA TI Method for structural modifying ***Clostridium*** neurotoxins for altering biological activity or persistence by leucine-based motifs				
IN Steward, Lance E.; Fernandez-Salas, Ester; Herrington, Todd M.; Aoki, Kei Roger PA Allergan Sales, Inc., USA SO PCT Int. Appl., 102 pp. CODEN: PIXXD2 DT Patent LA English FAN/CNT 5 PATENT NO. KIND DATE APPLICATION NO. DATE -----				
PI WO 2002/008268 A2 20020131 WO 2001-US23122 20010720 WO 2002/008268 A3 20030220 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 6903187 B1 20050607 US 2000-620840 20000721 CA 2416988 AA 20020131 CA 2001-2416988 20010720 EP 1309618 A2 20030514 EP 2001-959115 20010720 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR BR 2001012715 A 20030520 BR 2001-12715 20010720 NZ 523662 A 20050324 NZ 2001-523662 20010720 JP 2005517627 T2 20050616 JP 2002-514172 20010720 PRAI US 2000-620840 A 20000721 WO 2001-US23122 W 20010720				
AB The invention provides a method for structural modifying botulinum toxin with leucine-based motifs. Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological half-life and/or activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.				